May 2026– date –
-
Bloom X³ Founder & CEO Hiro Kimura Participated in Coolwater Capital’s Investor Summit and Strengthened US Engagement in San Francisco
Bloom X³ Founder & CEO Hiro Kimura participated in Coolwater Capital's Investor Summit in San Francisco, strengthening US engagement and confirming strong international interest in the firm's life science investment strategy and the 1102 incubation project. -
Research Collaboration with Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University, Enters Phase 2 — The 1102 Program Toward Aging, Rejuvenation, and Regenerative Medicine
Bloom X³ advances its research collaboration with Kansai BNCT Medical Center to Phase 2. The 1102 Program looks beyond intractable cancers, toward aging, rejuvenation, and regenerative medicine.
1